- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06902298
Personalisierte Ultraschallhirnstimulation bei Depressionen (R61)
Personalisierte Ultraschallhirnstimulation bei Depressionen: Eine Studie über Zielbindung und Stimmungseffekte
This study will evaluate a new form of non-invasive brain stimulation for individuals with depression. Personalized low-intensity transcranial focused ultrasound stimulation will be delivered using a range of stimulation parameters during psychological and physiological monitoring. Individualized optimal targets will be selected using structural MRI and diffusion tractography. Brain target engagement will be evaluated using functional MRI.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
This R61 project has 3 aims:
- To determine whether stimulation engages the subcallosal cingulate (SCC) in an intensity-dependent manner
- To examine the degree of specificity of neuromodulation by contrasting the neural effects of stimulating two spatially distinct targets versus sham
- To evaluate safety, tolerability, and side effects
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
- Phase 1
Kontakte und Standorte
Studienorte
-
-
Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84108
- University of Utah
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Age 18-65, any gender.
- Primary diagnosis of DMS-5 major depressive disorder (MINI).
- Current moderate-to-severe depressive episode, without psychotic features, lasting at least 2 months (MINI).
- Self-rated 16-item Quick Inventory of Depressive Symptomatology (QIDS) total score > 10.
- History of at least 2 failed trials of evidence-based antidepressant medication and/or psychotherapy (at least one trial during the current depressive episode).
- Stated willingness to comply with all study procedures and avoid changes to psychiatric treatments (medications, psychotherapy) for the duration of the study.
- For participants of reproductive potential: negative pregnancy test or use of highly effective contraception for at least 1 month prior to baseline; agreement to use such a method throughout the study.
- Capacity to provide informed consent; provision of a signed and dated consent form
- Currently are under the care of a licensed psychiatrist or other mental health care provider, or a licensed addiction medicine specialist and agrees to promptly inform the investigator or the study staff of any change in these providers.
- Agrees to allow any and all forms of communication between the investigators/study staff and any healthcare provider who currently provides and/or has provided service to the patient/subject within at least two years of study enrollment for the purposes of eligibility confirmation or in case of a safety event.
- Agrees to provide the name and verifiable contact information (email and mailing addresses, mobile and land-line phone numbers, as applicable) of at least two persons 22 years or older who reside within a 60-minute drive of the patient's residence. Subject agrees that in the event of a safety concern or event during study participation, research staff is at liberty to contact these individuals if the subject does not respond to contact attempts.
Exclusion Criteria:
- History of serious brain injury or other neurologic disorder.
- Poorly managed general medical condition.
- Pregnant or breast feeding.
- Implanted device in the head or neck.
- MRI intolerance or contraindication.
- Brain stimulation treatment such as ECT, TMS, or VNS (past month).
- Recent change in antidepressant treatments (past month).
- 8. Moderate-High Risk of Suicide according to the Columbia - Suicide Severity Rating Scale (C-SSRS) Screen Version - Recent (answers YES to Question 3 and NO to Question 6 (Moderate risk) or YES to Question 4, 5, or 6 (High risk)) and/or in the clinical judgement of the PI or a study psychiatrist
- Suicidal behavior (past year).
- Serious suicide attempt 33 (lifetime).
- Moderate-to-severe substance use disorder (MINI, past 3 months).
- Obsessive compulsive disorder, primary diagnosis (MINI, past month).
- Posttraumatic stress disorder, primary diagnosis (MINI, past month).
- Bipolar-spectrum disorder (MINI, lifetime).
- Schizophrenia-spectrum disorder (MINI, lifetime).
- Neurocognitive disorder (DSM-5, past year).
- Severe personality disorder.
- Clinically inappropriate for participation in the study as determined by the study team.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Grundlegende Wissenschaft
- Zuteilung: Zufällig
- Interventionsmodell: Crossover-Aufgabe
- Maskierung: Verdreifachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Group 1: SCC-ALIC
Low-intensity transcranial focused ultrasound stimulation (LTFUS) is delivered to the subgenual cingulate cortex (SCC) at the first stimulation visit, then LTFUS is delivered to the anterior limb of the internal capsule (ALIC) at the second stimulation visit. |
Low-intensity transcranial focused ultrasound delivered to subgenual cingulate cortex Low-intensity transcranial focused ultrasound delivered to anterior limb of internal capsule |
|
Experimental: Group 2: ALIC-SCC
Low-intensity transcranial focused ultrasound stimulation (LTFUS) is delivered to the anterior limb of the internal capsule (ALIC) at the first stimulation visit, then LTFUS is delivered to the subgenual cingulate cortex (SCC) at the second stimulation visit. |
Low-intensity transcranial focused ultrasound delivered to subgenual cingulate cortex Low-intensity transcranial focused ultrasound delivered to anterior limb of internal capsule |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Modulation of SCC activity during SCC stimulation
Zeitfenster: Days 14, 21, 28
|
Functional MRI is used to quantify modulation of SCC activity during SCC stimulation |
Days 14, 21, 28
|
|
Modulation of SCC activity during ALIC stimulation
Zeitfenster: Days 14, 21
|
Functional MRI is used to quantify modulation of SCC activity during ALIC stimulation |
Days 14, 21
|
|
Study dropout
Zeitfenster: From enrollment to the end of participation at 7 weeks
|
Dropout or withdrawal due to stimulation-related adverse effects |
From enrollment to the end of participation at 7 weeks
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
PANAS-X
Zeitfenster: Immediately before and after each LTFUS on Days 14, 21, 28
|
Positive and Negative Affect Schedule, Expanded Form |
Immediately before and after each LTFUS on Days 14, 21, 28
|
|
MADRS
Zeitfenster: Days 14, 21, 28, 35, 49
|
Montgomery-Asberg Depression Rating Scale |
Days 14, 21, 28, 35, 49
|
|
HDRS-6
Zeitfenster: Days 0, 14, 15, 21, 22, 28, 29, 35, 49
|
6-item Hamilton Depression Rating Scale |
Days 0, 14, 15, 21, 22, 28, 29, 35, 49
|
|
IDS-SR
Zeitfenster: Days 0, 14, 21, 28, 35, 49
|
Inventory of Depressive Symptomatology, Self-Rated |
Days 0, 14, 21, 28, 35, 49
|
|
GAD-7
Zeitfenster: Days 0, 14, 21, 28, 35, 49
|
7-item Generalized Anxiety Disorder Scale |
Days 0, 14, 21, 28, 35, 49
|
|
YMRS
Zeitfenster: Days 0, 14, 15, 21, 22, 28, 29, 35, 49
|
Young Mania Rating Scale |
Days 0, 14, 15, 21, 22, 28, 29, 35, 49
|
|
C-SSRS
Zeitfenster: Days 0, 14, 15, 21, 22, 28, 29, 35, 49
|
Columbia Suicide Severity Rating Scale, Screen Version |
Days 0, 14, 15, 21, 22, 28, 29, 35, 49
|
|
GASE
Zeitfenster: Days 15, 22, 29
|
Generic Assessment of Side Effects scale |
Days 15, 22, 29
|
|
MoCA
Zeitfenster: Days 14, 15, 49
|
Montreal Cognitive Assessment |
Days 14, 15, 49
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Brian J Mickey, University of Utah
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
- IRB_00148802R61
- R61MH134943 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .